Lipocine Inc. (LPCN)
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
$25.40M
Dr. Mahesh V. Patel Ph.D.
17.00
Salt Lake City, UT
Mar 21, 2014
-2.93
$-1.62
2.74
14.82
-124.52%
-1.10
0.10
0.46
1.40
14.44
-39.02%
-35.56%
Similar stocks (14)
Ardelyx, Inc.
ARDX
Kodiak Sciences Inc.
KOD
Verastem, Inc.
VSTM
Checkpoint Therapeutics, Inc.
CKPT
Fortress Biotech, Inc.
FBIOP
Eyenovia, Inc.
EYEN
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Unicycive Therapeutics, Inc.
UNCY
Cognition Therapeutics, Inc.
CGTX
Mustang Bio, Inc.
MBIO
TransCode Therapeutics, Inc.
RNAZ
Hepion Pharmaceuticals, Inc.
HEPA
Kiromic BioPharma, Inc.
KRBP
ZyVersa Therapeutics, Inc.
ZVSA
ETF Exposure (9)
Dimensional U.S. Targeted Value ETF
DFAT
2.6793e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
1.3589999999999999e-5%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (14)
Ardelyx, Inc.
ARDX
Kodiak Sciences Inc.
KOD
Verastem, Inc.
VSTM
Checkpoint Therapeutics, Inc.
CKPT
Fortress Biotech, Inc.
FBIOP
Eyenovia, Inc.
EYEN
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Unicycive Therapeutics, Inc.
UNCY
Cognition Therapeutics, Inc.
CGTX
Mustang Bio, Inc.
MBIO
TransCode Therapeutics, Inc.
RNAZ
Hepion Pharmaceuticals, Inc.
HEPA
Kiromic BioPharma, Inc.
KRBP
ZyVersa Therapeutics, Inc.
ZVSA
ETF Exposure (9)
Dimensional U.S. Targeted Value ETF
DFAT
2.6793e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
1.3589999999999999e-5%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%